ABBVIE INC. vs. Cue Biopharma, Inc.
ABBVIE INC. (ABBV) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| ABBV | CUE | |
|---|---|---|
| Market Cap | $467.37 billion | $269.15 million |
| Revenue (TTM) | $64.39 billion | $37.65 million |
| Net Income (TTM) | $6.32 billion | $-164,108,000 |
ABBV leads on 3 of 3 size & scale factors.
Valuation
| ABBV | CUE | |
|---|---|---|
| P/E Ratio | 74.71 | — |
| Price / Book | -79.38 | 116.51 |
| Price / Sales | 7.26 | 7.15 |
ABBV and CUE split the valuation factors evenly.
Profitability
| ABBV | CUE | |
|---|---|---|
| Net Margin | 9.81% | -435.83% |
| Return on Equity | -107.29% | -7104.24% |
ABBV leads on 2 of 2 profitability factors.
Dividend
| ABBV | CUE | |
|---|---|---|
| Dividend Yield | 2.62% | — |
| Payout Ratio | 195.48 | — |
ABBV and CUE split the dividend factors evenly.
Risk & Sentiment
| ABBV | CUE | |
|---|---|---|
| Short Interest | 0.85% | 0.48% |
CUE leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, CUE overview, CUE financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.